- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07941856
A Mixed-Method Study for Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Units
Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Unit Settings: A Mixed-Method Study
This is a phased mixed-method implementation study aiming to develop and evaluate a multi-component central-line-associated bloodstream infection (CLABSI) prevention bundle in three intensive-care units (Respiratory Intensive Care Unit, RICU; Surgical Intensive Care Unit, SICU; Neonatal Intensive Care Unit, NICU) at Peking University First Hospital. This study will first conduct pilot testing of the refined bundle in NICU, then scale-up implementation across all three ICUs. CLABSI incidence rate per 1000 central line-days is the primary outcome; bundle adherence rate and multi-dimensional implementation outcomes are secondary outcomes.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Shuo Li, M.D.
- 전화번호: +86-13671275323
- 이메일: shuoli_bjmu@126.com
연구 연락처 백업
- 이름: Xi Yao, MMSc
- 전화번호: +86-13811429675
- 이메일: yaoxi@pku.edu.cn
연구 장소
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100034
- 모병
- Peking University First Hospital
-
연락하다:
- Shuo Li, M.D.
- 전화번호: +86-13671275323
- 이메일: shuoli_bjmu@126.com
-
연락하다:
- Xi Yao, MMSc
- 전화번호: +86-13811429675
- 이메일: yaoxi@pku.edu.cn
-
수석 연구원:
- Liuyi Li, MMSc
-
수석 연구원:
- Hongling Chu, Ph.D.
-
수석 연구원:
- Xi Yao, MMSc
-
부수사관:
- Meihua Hu, MMSc
-
부수사관:
- Yuan Cheng, M.D.
-
부수사관:
- Tian Sang, M.D.
-
부수사관:
- Cui Yuan, MMSc
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Admitted to RICU, SICU or NICU of Peking University First Hospital during study period
- Has an indwelling central venous catheter (CVC, non-tunneled), peripherally inserted central catheter (PICC), or umbilical venous catheter (UVC)
- Generates central-line-days within study observation window
Exclusion Criteria:
- CVC placed in external hospitals and not managed within the three participating ICUs
- Central-line-days generated outside study observation period
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: CLABSI Prevention Bundle Intervention Arm
Single-group intervention, implementing multi-component CLABSI prevention bundle in NICU, RICU and SICU with phased roll-out |
A multi-component CLABSI prevention bundle with six core measures: (1) preferable insertion site selection, (2) hand hygiene, (3) maximum sterile barrier precautions, (4) catheter hub disinfection and insertion site care, (5) timely removal of non-essential catheters, and (6) implementation of a standardized checklist. The study adopts a phased implementation design: a pilot phase will first be conducted in NICU to test the bundle, identify implementation barriers, and refine local strategies; after optimization, the refined bundle will be rolled out across RICU, SICU and NICU. Local implementation teams will develop tailored action plans, monitor adherence, and iteratively optimize implementation strategies throughout the study. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
CLABSI incidence rate
기간: Baseline through intervention period, up to 36 months
|
CLABSI cases per 1000 central-line-days, defined according to Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) criteria. Calculated as number of CLABSI events divided by total central-line-days multiplied by 1000, collected prospectively in RICU, SICU and NICU. |
Baseline through intervention period, up to 36 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall CLABSI prevention bundle adherence score
기간: Baseline through implementation period, up to 36 months
|
A composite adherence score calculated as the mean proportion of correctly performed elements across six core CLABSI-prevention bundle measures (hand hygiene, maximum sterile barrier precautions, preferable insertion site, disinfection and site care, nonessential catheter removal, and checklist completion), assessed by direct observation and chart review. The score is expressed as a single percentage ranging from 0% to 100%. |
Baseline through implementation period, up to 36 months
|
|
Acceptability of the CLABSI prevention intervention bundle
기간: Entire study duration, up to 36 months
|
Acceptability will be assessed through semi-structured interviews with healthcare professionals involved in implementation to explore perceptions of whether the intervention bundle is agreeable and satisfactory in routine clinical practice. Findings will be reported as qualitative themes and categories. |
Entire study duration, up to 36 months
|
|
Fidelity of implementation of the intervention bundle - Quantitative assessment
기간: Entire study duration, up to 36 months
|
The degree to which the intervention bundle is implemented as intended according to predefined implementation procedures, assessed by quantitative process indicators, case audits, and checklists. Fidelity will be reported as the proportion of predefined procedures correctly completed. |
Entire study duration, up to 36 months
|
|
Fidelity of implementation of the intervention bundle - Qualitative assessment
기간: Entire study duration, up to 36 months
|
The degree to which the intervention bundle is implemented as intended, assessed through semi-structured interviews with implementation stakeholders. Qualitative findings regarding barriers and facilitators to implementation fidelity will be reported as themes. |
Entire study duration, up to 36 months
|
|
Feasibility of implementation of the intervention bundle
기간: Entire study duration, up to 36 months
|
Feasibility will be assessed through semi-structured interviews with healthcare professionals to determine the extent to which the intervention bundle can be successfully implemented within participating intensive care units. Findings will be reported as qualitative themes describing barriers and facilitators to implementation. |
Entire study duration, up to 36 months
|
|
Sustainability of implementation of the intervention bundle - Quantitative assessment
기간: Entire study duration, up to 36 months
|
The extent to which implementation of the intervention bundle is maintained over time, assessed using quantitative process indicators. Sustainability will be reported as the proportion of bundle elements continued in routine clinical practice. |
Entire study duration, up to 36 months
|
|
Sustainability of implementation of the intervention bundle - Qualitative assessment
기간: Entire study duration, up to 36 months
|
The extent to which implementation of the intervention bundle is integrated into routine clinical practice over time, assessed through semi-structured interviews. Qualitative findings will be reported as themes. |
Entire study duration, up to 36 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Shuo Li, M.D., Peking University First Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 2024-197-002
- 23-515 (기타 보조금/기금 번호: China Medical Board)
- 2024研197-002 (기타 식별자: Peking University First Hospital Ethics Committee)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual-participant data will not be shared publicly because of patient privacy restrictions and local institutional data security requirements. Aggregated study results may be published in peer-reviewed journals.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .